Metastasiertes Mammakarzinom: Mit CDK4/6-Inhibitoren die Zellteilung hemmen

Professor Jens Huober, „Einsatz von CKD4/6-Inhibitoren beim metastasierten Mammakarzinom heute“,  Professor Dr. Nadia Harbeck, „Weiterentwicklungen in der adjuvanten Behandlung“, Symposium, veranstaltet von Lilly im Rahmen des 33. Deutschen Krebskongresses, 21.2.2018, Berlin.

1. Finn et al. (2016): Palbociclib and Letrozole in Advanced Breast Cancer. New England Journal of Medicine, DOI: 10.1056/NEJMoa1607303
2. Hortobagyi et al. (2017): Updated results from MONALEESA-2, a phase 3 trial of first-line ribociclib + letrozole in hormone receptor-positive (HR+), HER2-negative (HER2–), advanced breast cancer (ABC). Journal of Clinical Oncology, ASCO 2017, DOI: 10.1200/JCO.2017.35.15_suppl.1038
3. Cristofanilli et al. (2016): Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. The Lancet Oncology, DOI: https://doi.org/10.1016/S1470-2045(15)00613-0
4. Sledge et al. (2017): MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. Journal of Clinical Oncology DOI: 10.1200/JCO.2017.73.7585
5. Hurvitz et al. (2016): Biological effects of abemaciclib in a phase 2 neoadjuvant study for postmenopausal patients with HR+, HER2-breast cancer. San Antonio Breast Cancer Symposium 2016, Abstract # S4_06
6. Cottu et al (2017): Letrozole and palbociclib versus 3rd generation chemotherapy as neoadjuvant treatment of luminal breast cancer. Results of the UNICANCER-NeoPAL study. ESMO 2017 Madrid, Abstract # LBA9